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Abstract
CD98 heavy chain (CD98hc) is a multifunctional transmembrane spanning scaffolding protein whose extracellular domain
binds with light chain amino acid transporters (Lats) to form the heterodimeric amino acid transporters (HATs). It also
interacts with b1 and b3 integrins by its transmembrane and cytoplasmic domains. This interaction is proposed to be the
mechanism whereby CD98 mediates cell survival and growth via currently undefined signaling pathways. In this study, we
determined whether the critical function of CD98-dependent amino acid transport also plays a role in cell proliferation and
defined the signaling pathways that mediate CD98-dependent proliferation of murine renal inner medullary collecting duct
(IMCD) cells. We demonstrate that downregulating CD98hc expression resulted in IMCD cell death. Utilizing overexpression
studies of CD98hc mutants that either lacked a cytoplasmic tail or were unable to bind to Lats we showed that CD98
increases serum-dependent cell proliferation by a mechanism that requires the CD98hc cytoplasmic tail. We further
demonstrated that CD98-dependent amino acid transport increased renal tubular epithelial cell proliferation by a
mechanism that does not require the CD98hc cytoplasmic tail. Both these mechanisms of increased renal tubular epithelial
cell proliferation are mediated by Erk and p38 MAPK signaling. Although increased amino transport markedly activated
mTor signaling, this pathway did not alter cell proliferation. Thus, these studies demonstrate that in IMCD cells, the
cytoplasmic and extracellular domains of CD98hc regulate cell proliferation by distinct mechanisms that are mediated by
common MAPK signaling pathways.
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Introduction
The heterodimeric amino acid transporters consist of a type II
transmembrane protein heavy chain and a light chain linked by an
extracellular disulfide bridge [1,2]. The heavy chain subunits
rBAT and CD98hc (also called 4F2hc) heterodimerize with a
number of light chain amino acid transporters [3,4]. The principal
function of the heavy chain is to localize the heterodimer to either
the apical or basolateral aspect of the cell [1,2]. CD98 is expressed
in all cell types with the exception of platelets and its highest levels
of expression are in the tubules of the kidney and the
gastrointestinal tract [1,2,5], where it plays a critical role in the
vectorial transport of amino acids across a polarized epithelium.
CD98 is required for normal development in mammals and
deletion of CD98hc results in early embryonic lethality in mice [6].
CD98hc heterodimerizes with one of the light chains Lat-1,
Lat2, y
+Lat-1, y
+Lat2 and xCT [7–16] and is required for the
surface expression of the heterodimers. These transporters mediate
Na
+-independent transport of large neutral amino acids (e.g.
leucine) and/or Na
+-dependent co-transport of positively charged
amino acids (e.g. arginine) and neutral amino acids [1,2]. In
addition to the light chain, CD98hc associates with b integrins
[17–26]. This association is important for altering integrin affinity
and integrin dependent signaling resulting in alterations in cell
differentiation, proliferation, aggregation, adhesion, migration and
malignant transformation [17–21,23–26]. The physiological rele-
vance of CD98 function was investigated in mice by either deleting
or overexpressing CD98hc [23,24,27–30]. Constitutive deletion of
CD98hc resulted in early embryonic lethality [6]. Specifically
deleting CD98hc from lymphocytes [27,28] and vascular smooth
muscle [29] decreased proliferation of both cell types and altered
adaptive humoral immunity or resulted in abnormal vessel repair
in the organ specific null mice. CD98hc overexpression in the
gastrointestinal epithelium induced tumorigenesis by causing
barrier dysfunction and stimulating cell proliferation, whereas
CD98hc deletion resulted in an attenuated inflammatory response
as well as resistance to DSS-induced colitis and colitis-associated
tumorigenesis [30]. Together these in vivo data emphasize the
important role CD98 plays in regulating cell proliferation in
multiple cell types.
The mechanism whereby CD98 modulates cell proliferation is
not fully understood. Increased amino acid transport increases
cell proliferation [31–33], however mechanisms other than this
also probably play a role in CD98-dependent proliferation as
mutants of CD98hc unable to associate with amino acid
transporters can induce malignant transformation of NIH3T3
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no effect on amino acid transport have been shown to be
important in modulating CD98-dependent transformation [18],
survival [23,27,35], proliferation [23,27,29,30,35], adhesion
[18,26], migration [18,26] and tubule formation [26]. PI3-kinase
[18,26], Rho A [23] and focal adhesion kinase [18,26] signaling
have been implicated in mediating CD98/b1 integrin-dependent
cell spreading, migration, transformation and survival. The
relative roles of CD98-dependent amino acid transport and
other as yet undefined signaling pathways on cell proliferation
are currently unclear.
Based on the in vivo and in in vitro data showing a
requirement for CD98 for cell survival and proliferation, we
investigated the mechanisms whereby CD98 regulates these
cellular processes in polarized renal epithelial cells. We
demonstrate that CD98hc expression is required for these cells
to survive, as deleting or downregulating CD98hc expression
results in cell death. Utilizing overexpression studies of mutants
of CD98hc and Lat-1 we show that CD98 increases cell
proliferation by two distinct mechanisms that signal through
MAPKs. One requires the CD98hc cytoplasmic tail and is
independent of changes in amino acid transport. The second is
due to increased CD98-dependent amino acid transport and
does not require the CD98hc cytoplasmic tail. Thus CD98
modulates cell proliferation by two distinct mechanisms, namely
the induction of signaling via its cytoplasmic tail and its ability
to increase amino acid transport into cells.
Results
CD98 is Required for Inner Medullary Collecting Duct
(IMCD) Cell Survival
Consistent with previous reports demonstrating that CD98
expression increases cell proliferation [23,27,29,30,35], we ob-
served that IMCD cells (which are derived from the kidney
collecting ducts) overexpressing CD98 proliferated more rapidly
than wild type IMCD cells under normal culture conditions. To
define the molecular mechanisms of this increased cell prolifera-
tion, we initially attempted to downregulate CD98hc in IMCD
cells using 3 different hairpin siRNAs expressed by lentiviruses.
Although we successfully downregulated CD98hc expression using
all 3 lentiviruses, the cells died within a week (data not shown). We
next attempted to generate IMCD cells from CD98hc floxed mice
and delete the gene in vitro using cre recombinant adenovirus.
While we were able to obtain CD98hc
fl/fl cells, we were unable to
obtain CD98hc-null cells, as they also died within a week (data not
shown). To demonstrate the requirement for CD98hc for IMCD
cell survival, we transfected CD98hc
fl/fl cells with a human
CD98hc cDNA and then deleted the floxed gene in vitro with
adeno cre. In figure 1, we show that CD98
fl/fl cells treated with cre
show increased caspase-3 activation and this correlates with the
degree of downregulated mouse CD98hc protein. In contrast, we
did not detect any caspase-3 activation in CD98
fl/fl cells that
expressed human CD98hc following cre treatment. All the cre-
infected CD98hc
fl/fl IMCD cells died eventually, while the
reconstituted cells survived and continued proliferating. Thus,
deleting CD98hc results in significant IMCD cell apoptosis
suggesting these cells require CD98hc for survival.
The Cytoplasmic Tail of CD98 is Required to Induce
Serum Dependent Cell Proliferation
Due to our failure to establish CD98hc-null cell populations we
utilized previously generated IMCD cells that overexpress full
length (CD98) and mutants of human CD98hc [26] to define how
CD98 regulates cell proliferation. The mutants (Figure 2A) either
lacked the first 77 amino acids of the cytoplasmic tail (CD98-77),
the full putative cytoplasmic tail (CD98-82) or the cytoplasmic tail
as well as the N-terminal five amino acids (WALLL) of the
transmembrane domain (CD98-87), which we have shown to be
critical for CD98 to interact with the b1 integrin and regulate
integrin dependent cell adhesion, migration and tubulogenesis
[26]. Equal expression of these mutants in the IMCD cells was
verified by flow cytometry with an antibody directed against the
extracellular domain of human CD98hc, which demonstrates that
the CD98hc is expressed on the cell surface [26]. We further
showed that all of these mutants are expressed in membranes by
performing western blot analysis with an antibody directed against
human CD98hc on cytosolic and membrane fractions derived
from the IMCD cells (Figure 2B).
We defined the role of CD98 on IMCD cell proliferation in cells
grown in complete medium containing low levels (1%) of serum
(Figure 2C). CD98 cells showed a 2 fold increase in cell
proliferation relative to IMCD cells and consistent with this result,
there was increased cyclin D1 expression in CD98 cells 4 hours
after the addition of complete medium (Figure 2D). By contrast,
there was only approximately a 35% increase in proliferation in
the CD98-77, CD98-82 or CD98-87 deletion mutants (Figure 2C).
These results suggest that increased CD98hc expression enhances
cell proliferation in complete medium by a mechanism that
requires the 77 amino acid cytoplasmic tail and another that does
not.
CD98 Regulates Serum-dependent Cell Proliferation by
Increasing Erk and p38 MAPK Signaling
Complete medium, which includes fetal calf serum, increases
cell proliferation by altering many different signaling pathways.
Because the data presented above suggests that the CD98hc
cytoplasmic tail regulates cell proliferation and CD98hc has been
demonstrated to activate specific integrin-dependent signaling
pathways [17–19], we initially defined whether there were
differences in serum-dependent (complete medium with 10%
serum) activation of PI3K, Erk and p38 MAPK signaling between
IMCD cells and CD98 cells. In contrast to the changes seen in
integrin-dependent signaling where the PI3K pathway was
Figure 1. CD98 is required for IMCD cell survival. CD98
fl/fl IMCD
cells or CD98
fl/fl IMCD cells reconstituted with human CD98 (CD98
fl/
flhCD98) were infected with adeno-cre virus after which they were
harvested at different time points and immunoblotted for cleaved
caspase-3, mouse CD98hc, human CD98hc or actin.
doi:10.1371/journal.pone.0040026.g001
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the wild type and CD98 cells. There was however earlier and
more pronounced Erk and p38 MAPK activation in the CD98
cells (Figure 3A). To define whether this increased signaling
altered cell proliferation, thymidine incorporation assays were
performed in low serum medium (1%) in the presence and absence
of the PI3K inhibitor LY294002, the MEK inhibitor U0126 and
the P38 MAPK inhibitor SB203580 (Figure 3B). IMCD cell
proliferation was decreased by 40% with the MEK inhibitor;
however CD98 cell proliferation was significantly decreased by
both the MEK (40%) and p38 MAPK (25%) either added alone or
in combination.
Because overexpression of CD98 increases amino acid transport
and amino acids are well known to stimulate the mTor pathway,
we defined the role of this pathway in modulating proliferation of
CD98 cells. We assessed whether the mTor pathway was activated
by defining the phosphorylation state of p70S6K and 4EBP1, both
of which are downstream of mTorc1. Adding complete medium
with 10% serum stimulated phosphorylation of p70S6K only in
CD98 cells and, although the phosphorylation pattern of 4EBP1
was similar in both cell lines, there was a more robust signal in
CD98 cells 30 minutes after stimulation (Figure 3C). Despite
increased mTOR downstream signaling in CD98 cells, addition of
the mTor inhibitors Rapamycin or PP242 did not alter cell
proliferation (figure 3D). These results suggest that proliferation of
IMCD cells, which is increased in cells overexpressing CD98, is
dependent on Erk and p38 MAPK but not mTor or PI3K
activation.
IMCD Cell Proliferation is Increased in Response to CD98-
dependent Enhanced Amino Acid Transport
CD98hc interacts with the Lat transporters via its extracellular
domain and increases CD98-dependent amino acid transport. To
define the role of amino acid transport by CD98 on cell
proliferation we generated IMCD cells that overexpressed Cless,
a previously defined mutant of CD98hc where the two cysteines in
the extracellular domain are mutated making it unable to interact
with the HAT light chains [36]. This population of cells expressed
Cless at the same level as CD98 as verified by flow cytometry (data
not shown). As expected, overexpressing CD98 alone caused a
40% increase in isoleucine transport relative to IMCD cells which
was not seen in the Cless cells (Figure 4A). When proliferation in
complete medium with 1% serum was determined in the Cless
IMCD cells, there was only a 50% increase, while there was over a
2 fold increase in the CD98 cells compared to IMCD cells
(Figure 4B). These data suggest that the extracellular domain of
CD98 increased proliferation in the CD98 cells by inducing
additional amino acid transport.
To further explore the effects of amino acid transport of HATs
on IMCD cell proliferation, we generated IMCD cells that
overexpressed the amino acid transporter Lat-1 in conjunction
with CD98hc. We utilized a Flag-tagged Lat-1 for these over-
expression studies. Lat-1 is endogenously expressed in IMCD cells
Figure 2. The cytoplasmic tail of CD98 is required for serum-dependent cell proliferation. (A) Schematic representation of the CD98
constructs used for CD cell transfection. CD, cytoplasmic domain; TM, transmembrane domain; EC, extracellular domain. (B) Full-length CD98hc and
its truncation mutants are expressed in membrane fractions of IMCD cells. IMCD cells expressing CD98hc or the different truncation mutants were
fractionated into cytoplasmic (Cyt) Triton X-100–soluble and – insoluble membrane fractions (MF). These fractions were subjected to SDS-PAGE and
immunoblotted with an antibody directed against human CD98hc. (C) CD98hc induces cell proliferation in serum. IMCD were plated onto 96-well
plates, serum deprived for 24 hours then treated for 16 hours with
3H-Thymidine in media containing 1% serum.
3H-Thymidine incorporation was
determined as described in Experimental Procedures. Values are the mean 6 s.e.m. of a representative experiment performed in eight replicates. (*)
indicates statistically significant differences (p,0.05) between CD98 and deletion mutants. (**) denotes a statistically significant difference between
CD98 and IMCD. (D) Time course of Cyclin D1 expression. Sub-confluent cells were serum deprived for 24 hours and then treated with complete
medium. Lysates were isolated at the time points indicated and analyzed by SDS-PAGE.
doi:10.1371/journal.pone.0040026.g002
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cells (3 shown) which overexpressed Lat-1. We subsequently
overexpressed CD98 or the truncation mutants of CD98-77,
CD98-82 and CD98-87 into the Lat-1 overexpressing cells and
sorted for equal expression by flow cytometry (data not shown). To
verify that Lat-1 heterodimerized with CD98hc or the mutants, we
immunopreciptated CD98hc from the different IMCD cell
populations and immunoblotted the precipitates with antibodies
directed against either CD98hc (Figure 5B, upper panel) or Flag
(Figure 5B, lower panel). It is clear that Lat-1 was part of the HAT
complex in non-reducing conditions and that it became disasso-
ciated from CD98hc under reducing conditions. Thus, the HAT
complex was formed by CD98hc and all the mutants.
We initially examined the effect of overexpressing Lat-1 in the
IMCD cells. Like CD98 cells, the Lat-1 expressing cells had a
small but significant (40%) increase in isoleucine transport when
compared to IMCD cells, while expressing both CD98 and Lat-1
resulted in an 2 fold increase in isoleucine transport (Figure 5C).
Consistent with this increase in amino acid transport there was a
40% increase in proliferation of IMCD/Lat-1 cells relative to
wildtype IMCD cells in low serum medium. Furthermore, cells
overexpressing Lat-1 increased CD98 cell proliferation by an
additional 38% such that these cells proliferated 2.4 fold more
than IMCD cells (Figure 5D). Similar to CD98 cells, expressing
the Lat-1 transporter increased cell proliferation of cells of CD98-
77, CD98-82 and CD98-87 cells by 40% in low serum medium
(Figure 5E). These studies further confirm that CD98-dependent
amino acid transport increased proliferation by a mechanism that
does not require the CD98hc cytoplasmic tail.
Increased Transport of Amino Acids by CD98 Induces
Activation of Erk and p38 MAPK Pathways which
Enhance Cell Proliferation
Due to the observation that overexpression of CD98 increased
proliferation of cells grown in complete medium with serum by
increasing amino acid transport, we developed conditions (see
methods) to define the mechanisms whereby CD98 regulates
proliferation in the absence of serum. When CD98 cells were
placed in DMEM that did not contain serum they proliferated
60% more than IMCD cells as measured by thymidine
Figure 3. CD98 regulates serum dependent cell proliferation by increasing Erk and p38 MAPK signaling. (A, C) CD98hc expression
increases MAPK, Akt and mTor signaling in response to serum. Subconfluent cells were serum deprived for 24 hours then treated with complete
medium. Lysates were prepared at the time points indicated and analyzed by western blot with the antibodies indicated. (B, D) MAPK regulates
CD98hc-dependent IMCD cell proliferation. Cells seeded onto 96-well plates were serum deprived for 24 hours, pretreated with inhibitors prior to
addition of
3H-Thymidine in complete medium as described in Experimental Procedures. U+SB denotes concomitant treatment with the MEK
inhibitor U0126 (U) and the p38 MAPK inhibitor SB203580 (SB). (*) indicates statistically significant differences (p,0.05) between treated and
untreated cells. (**) denotes statistically significant differences between U+SB versus either inhibitor alone.
doi:10.1371/journal.pone.0040026.g003
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seen in the Cless cells; but proliferation was more than 3 fold and
double in the CD98/Lat-1 cells when compared to IMCD and
CD98 cells respectively. Consistent with the markedly increased
proliferation of the CD98/Lat-1 cells there was increased
expression of cyclin D1 when compared to IMCD cells
(Figure 6B). Thus CD98 significantly increases cell proliferation
in the setting of exposure only to amino acids, confirming this as a
mechanism of regulating cell proliferation.
We next investigated which pathways regulated CD98 depen-
dent cell proliferation in response to amino acids. We initially
defined the roles of Erk, Akt and p38 MAPK signaling by serum
and amino acid starving IMCD and CD98/Lat-1 cells which were
then exposed only to amino acids. Similar to the results seen when
the cells were exposed to complete medium with serum, increased
Erk and p38 MAPK but not Akt signaling was seen in the CD98/
Lat-1 compared to the control IMCD cells (Figure 6C). We tested
the role of these pathways in increasing the proliferation of the
CD98/Lat-1 cells by exposing them to specific inhibitors of these
pathways. As shown in Figure 6D, inhibiting MEK and p38
MAPK significantly decreases cell proliferation in both cell
populations, while the PI3 kinase inhibitors have no effect.
Furthermore, there was an additive effect of the MEK and p38
MAPK inhibitors, suggesting that these pathways acted synergis-
tically to support CD98/Lat-1 cell proliferation.
Increased Amino Acid Transport by CD98 Induces
Activation of the mTor Pathway; however this Pathway is
not Required for Enhanced Cell Proliferation
Because of the effects of amino acids on the mTor pathway, we
defined the effects of medium containing only amino acids on this
pathway in CD98/Lat-1 cells. As shown in figure 7A there were
markedly increased levels of activation of p70S6K in the CD98/
Lat-1 cells. Consistent with this observation there was strikingly
elevated phosphorylation of the slower migrating forms of
4EBP1.Taken together, these results confirm that the mTor
pathway is dramatically activated when the CD98/Lat-1 cells are
exposed to amino acids.
We next defined the role of this highly activated pathway in
inducing the increased proliferation of the CD98/Lat-1 cells in
serum free medium by growing them in the presence of
Rapamycin and PP242 (Figure 7B). Addition of either of these
inhibitors did not alter CD98/Lat-1 cell proliferation, despite the
fact that they inhibited phosphorylation of the downstream targets
of mTor, p70S6K and 4EBP1 (Figure 7C). The PI3 kinase
inhibitor LY294002, which is also an inhibitor of mTor did not
alter cell proliferation although it significantly decreased amino
acid activation of the mTor pathway. By contrast, the MEK and
p38 MAPK inhibitors which inhibit cell proliferation do not alter
activation of the mTor pathway (Figure 7D). Thus although
overexpression of CD98 leads to increased amino acid transport
and activation of the mTor pathway, it does not play a role in cell
proliferation.
Discussion
A key function of the scaffolding protein, CD98hc, is to regulate
cell proliferation. In this manuscript we demonstrate that CD98hc
is required for the survival of polarized renal collecting duct cells
and that it promotes cell proliferation by two distinct mechanisms.
The CD98hc cytoplasmic tail promotes IMCD cell proliferation in
response to complete medium with serum by activating Erk and
p38 MAPK signaling. In addition, the extracellular domain of
CD98hc promotes cell proliferation by increasing amino acid
transport which activates the same signaling pathways. Although
increased amino transport stimulates mTor signaling, this does not
alter cell proliferation (Figure 8). These data clearly show that in
polarized renal epithelial cells, the cytoplasmic and extracellular
domains of CD98hc regulate cell proliferation by distinct
mechanisms that are mediated by common signaling pathways.
We demonstrate that knocking down CD98 by siRNA or
genetically deleting it from CD98
flox/flox collecting duct cells
resulted in their death, which confirmed that CD98 is required for
cell survival. These results are consistent with the early embryonic
(E3.5 to 9) lethality of CD98 null mice [6]. The severe phenotype
in IMCD cells lacking CD98 is likely not only due to its ability to
interact with b1 integrin as b1-null collecting duct cells survive and
proliferate [37]. We cannot exclude the possibility that CD98/b3
Figure 4. IMCD cell proliferation increases in response to enhanced amino acid transport. (A) CD98 expression increases isoleucine
transport.
3H-Isoleucine uptake was performed as described in Experimental Procedures. Cless cells are IMCD transfected with a CD98 mutant unable
to interact with Lats. (*) denotes statistically significant differences (p,0.05) between IMCD and CD98 cells. (B) Transfected IMCD cells were plated
onto 96-well plates, serum deprived for 24 hours then treated for 16 hours with
3H-Thymidine in media containing 1% serum.
3H-Thymidine
incorporation was determined as described in Experimental Procedures. Values are the mean 6 s.e.m. of a representative experiment performed in
eight replicates. (*) indicates statistically significant differences (p,0.05) between IMCD and Cless cells. (**) denotes statistically significant differences
between CD98 and Cless cells.
doi:10.1371/journal.pone.0040026.g004
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e40026Figure 5. CD98hc and Lat-1 increase cell proliferation. (A, B) Overexpressed Lat-1 interacts with CD98hc and CD98hc deletion mutants. (A)
Western blot analysis of clones of IMCD cells transfected with Lat-1. Total Akt was used as a loading control. (B) Cells overexpressing CD98 or CD98
deletion mutants as well as Flag-tagged human Lat-1 were lysed and immunoprecipitated with a human specific CD98 antibody. Non-reduced (NR)
and reduced (R) immunoprecipitates were separated by SDS-PAGE and immunoblotted with either a human specific CD98 antibody (upper panel) or
Flag antibody (lower panel). (C, D) Co-expression of CD98hc and Lat-1 increases amino acid transport and cell proliferation. (C)
3H-Isoleucine uptake
was performed as described in Experimental Procedures. IMCD/Lat-1cells are IMCD cells transfected with Lat-1 only and CD98/Lat-1 cells were the
Lat-1 cells that were further transfected with CD98 and selected by flow cytometry. (*) denotes statistically significant differences (p,0.05) compared
to IMCD cells whereas (**) indicates significant differences compared to CD98 cells. (D) Transfected cells were plated onto 96-well plates, serum
deprived for 24 hours then treated for 16 hours with
3H-Thymidine in media containing 1% serum.
3H-Thymidine incorporation was determined as
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ation in these cells because they do express b3 integrins (data not
shown). A more likely explanation for the requirement of CD98hc
for IMCD cell survival is that CD98 also facilitates critical aspects
of amino acid transport. This is consistent with the observation
that mice expressing CD98hc that lacks an extracellular domain
die between E7.5 and E 9.5 [38].
CD98 is required for proliferation of B and T lymphocytes
[27,28], vascular smooth muscle cells [29] and intestinal epithelial
cells [30] in the setting of different in vivo injury models. In the
lymphocyte and vascular smooth muscle studies, an interaction
between integrins and CD98hc were shown to be required for the
proliferative response. Our deletion mutant results demonstrate
that the CD98hc cytoplasmic tail is required for these proliferative
responses and the critical amino acids required for signaling are
distal to the membrane proximal 5 amino acids. We previously
demonstrated that an interaction between CD98hc and b integrins
requires either the transmembrane domain or the proximal part of
the cytoplasmic tail of CD98hc [26]. Thus although an integrin/
CD98hc interaction may be necessary to promote proliferation,
described in Experimental Procedures. Values are the mean 6 s.e.m. of a representative experiment performed in eight replicates. (*) indicates
statistically significant differences (p,0.05) compared to IMCD cells. (**) denotes a statistically significant difference between CD98 and CD98/Lat-1.
(E) Cells expressing CD98 deletion mutants and Lat-1 proliferated less than CD98/Lat-1 cells. IMCD cells overexpressing Lat-1 were transfected with
either CD98 or CD98 deletion mutant constructs described in Fig.1. Thymidine incorporation was determined as described above. Values are the
mean 6 s.e.m. of a representative experiment performed in eight replicates. (*)indicates statistically significant differences (p,0.05) between double
transfectants and cells transfected with CD98 or deletion mutants only.
doi:10.1371/journal.pone.0040026.g005
Figure 6. CD98hc/Lat-1-dependent amino acids transport increases cell proliferation mediated by Erk- and p38 MAPK. (A) CD98hc/
Lat-1-dependent amino acids transport increases cell proliferation. Cells were plated onto 96-well plates, serum deprived for 24 hours then deprived
of amino acids for 2 hours.
3H-Thymidine was then added in serum free media with a full complement of amino acids for an 8 hour pulse.
3H-
Thymidine incorporation was determined as described in Experimental Procedures. Values are the mean 6 s.e.m. of a representative experiment
performed in eight replicates. (*)indicates statistically significant differences (p,0.05) compared to IMCD cells. (**) denotes a statistically significant
difference between CD98 and CD98/Lat-1. (B, C) treatment of CD98/Lat-1 cells with amino acids increases cyclin D1 expression and MAPK activation.
Cells were serum deprived for 24 hours then subjected to amino acid deprivation for an additional two hours (time 0). Cells were then treated with
serum free media containing a full complement of amino acids and lysates were isolated at the time points indicated. Lysates were analyzed by SDS-
PAGE and immunoblots were performed with the antibodies against cyclin D1 (B) and Erk, Akt and p38 MAPK. b-Actin is a loading control (C). (D)
MAPK increases CD98/Lat-1 dependent amino acid induced proliferation. Cells were plated onto 96-well plates, serum deprived for 24 hours then
deprived of amino acids for an additional 2 hours and pretreated with inhibitors prior to addition of
3H-Thymidine in serum free media with a full
complement of amino acids for an 8 hour pulse.
3H-Thymidine incorporation was determined as described in Experimental Procedures. Values are the
mean 6 s.e.m. of a representative experiment performed in eight replicates. (*) indicates statistically significant differences (p,0.05) compared to
untreated cells. U+SB denotes concomitant treatment with the MEK inhibitor U0126 (U) the p38 MAPK inhibitor SB203580 (SB). (**) denotes
statistically significant differences between U+SB versus either inhibitor alone.
doi:10.1371/journal.pone.0040026.g006
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tail are required to mediate these effects.
We demonstrate that overexpression of CD98hc resulted in
increased activation of Erk, p38 MAPK and p70S6 kinase
following treatment of cells with medium containing serum;
however proliferation was only dependent on activation of Erk and
p38 MAPK. These observations contrast with the cell signaling
pathways modulated by CD98 following integrin ligation where
FAK [18,26], PI3-kinase [18,23,26] and Rac [23] but not Erk [26]
were activated and regulated cell adhesion, migration and
transformation of different cell types. Thus CD98 controls
different pathways in the setting of integrin ligation and growth
factor stimulation, which in turn modulate different cell functions.
Our data clearly demonstrates that in the setting of overex-
pression of CD98hc, cell proliferation is regulated by the transport
of amino acids in addition to mechanisms mediated by the
cytoplasmic tail which may, at least in part, require the interaction
of CD98hc with integrins. This effect was even more obvious when
we overexpressed Lat-1, which resulted in more significant amino
acid transport than only overexpressing CD98hc. These results
suggest that overexpressing CD98hc increases the surface expres-
sion of the Lats in IMCD cells, with consequent increased amino
acid transport and cell proliferation. This is further emphasized
when we co-express both the CD98hc and Lat-1. Our results
contrast with studies on lymphocytes and vascular smooth muscle
where only the interaction with integrins was required for the
increased proliferative response. However they are consistent with
multiple other studies where cellular proliferation is affected when
the Lat amino acid transporters are overexpressed, decreased or
when their function is inhibited [39,40]. A potential reason for the
differences in our findings and those in the lymphocytes and
vascular smooth muscle cells are that our studies are performed on
cells where CD98 is overexpressed, while those are on cells where
CD98hc is deleted. Furthermore epithelial cells in the kidney have
some of the highest expression levels of CD98 in the body which
may potentiate their importance for cell proliferation and survival.
Increased Erk and p38 MAPK but not Akt activation was
observed in serum starved CD98/Lat-1 cells treated with amino
Figure 7. mTOR pathway is activated by amino acids but does not affect amino acid-dependent proliferation. (A) Amino acid
treatment increases mTor signaling in CD98/Lat-1 cells. Cells were serum deprived for 24 hours then subjected to amino acid deprivation for an
additional two hours (time 0). Cells were then treated with serum free media containing a full complement of amino acids. Lysates were isolated at
the time points indicated and subjected to SDS-PAGE. Immunoblots were probed with phos-p70S6K (Thr389) as well as antibodies recognizing the
multiple phosphorylated forms of 4EBP1. (B) mTor pathways do not regulate amino acid-dependent proliferation of CD98/Lat-1 cells. Cells were
plated onto 96-well plates, serum deprived for 24 hours then deprived of amino acids for an additional 2 hours and pretreated with Rapamycin
(100 nM) and PP242 (2.5 mM) prior to addition of
3H-Thymidine in serum free media with a full complement of amino acids for an 8 hour pulse.
3H-
Thymidine incorporation was determined as described in Experimental Procedures then. Values are the mean 6 s.e.m. of a representative experiment
performed in eight replicates. (C and D) Inhibitors of mTor, MAPK and PI3 kinase were effective in inhibiting amino acid-dependent signaling. (C) Cells
were serum deprived for 24 hours then subjected to amino acid deprivation for an additional two hours (time 0) and pretreated with Rapamycin and
PP242 . Cells were treated with serum free media containing a full complement of amino acids in the presence of inhibitors. Lysates were isolated
after 2hours of amino acid treatment and subjected to SDS-PAGE. Immunoblots were probed with phos-p70S6K (Thr389) as well as an antibody
recognizing the hyperphosphorylated forms of 4EBP1. (D) Cells were treated as described in C in the presence of LY294002, SB 203580 and U0126, all
at 10 mM. Lysates were isolated after two hours of amino acid treatment in the presence of inhibitors and subjected to SDS-PAGE.
doi:10.1371/journal.pone.0040026.g007
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it was recently reported that amino acids can activate mTORC2
in a PI3K/Akt-dependent manner [41]. Furthermore, this result
effectively rules out the involvement of mTORC2 in the
proliferative response of CD98/Lat-1 cells. A marked increase in
Erk was present in the amino acid deprived CD98/Lat-1 cells.
This is one of the key mechanisms whereby cells can adapt to stress
induced by amino acid deprivation as sustained Erk activation
increases p21(cip1/waf1) which blocks cell cycle progression and
contributes to activation of the GCN2-eIF2a-ATF4 survival
pathway [42–44]. Erk phosphorylation was increased when
CD98/Lat-1 and IMCD cells were treated with amino acids
and this was accompanied by increased p38 MAPK signaling.
Inhibiting these pathways individually decreased cell proliferation
and there was an additive effect of inhibiting both pathways
together, suggesting that they activate proliferation independently
from each other. Amino acid-dependent Erk and p38 MAPK
activation has been shown to alter signaling of the MAPK-
activated protein kinases such as p90 ribosomal S6 kinase (RSK),
mitogen-and-stress-activated kinase (MSK) and possibly MAPK-
interacting kinases (MNK) [45,46]. Because these multifunctional
kinases regulate numerous cellular processes including cell
proliferation, this is the likely mechanism whereby CD98-
dependent amino acid transport regulates cell proliferation in
collecting duct cells.
We originally hypothesized that the increased proliferation in
CD98/Lat-1 cells, where there was markedly increased amino
acid transport, would lead to activation of the mTOR pathway. As
expected when starved IMCD cells were treated with serum or
amino acids, there was phosphorylation of the two best
characterized targets of mTOR, 4EBP1 and S6K1 and this was
markedly increased in CD98/Lat-1 cells. These effects were
readily reversed by Rapamycin and the mTOR kinase antagonist
PP242 a more effective ATP-competitive inhibitor that targets
both mTORC1 and mTORC2 [47]. In addition, phosphorylation
of both 4EBP1 and S6K1 was inhibited by the PI3K inhibitor
LY294002 that is now known to inhibit mTOR as well as class III
PI3K hVps34 [48,49]. However, despite marked activation of the
mTOR pathway, inhibiting it did not alter cell proliferation. Thus
only the Erk and p38 MAPK pathways are important for the
proliferative response of the CD98/Lat-1 IMCD cells.
Cyclin D1 was undetectable in amino acid deprived cells but its
expression was restored upon amino acid treatment with an earlier
recovery in CD98/Lat-1 cells. By contrast, inhibitor studies
showed that Cyclin D1 was regulated by all three pathways
activated by amino acid treatment. Treatment with Rapamycin,
PP242 as well as LY294002 led to drastic inhibition of Cyclin D1
expression, although as mentioned previously, these inhibitors had
no effect on cell proliferation following amino acid supplementa-
tion. On the other hand, treatment with the MEK inhibitor
U0126 and the p38 MAPK inhibitor SB203580 effectively
suppressed Cyclin D1 expression as well as inhibiting proliferation.
Cyclin D1 is a key target of amino acids in hepatocytes and its
overexpression can overcome cell cycle arrest induced by non-
essential amino acid deprivation under mitogenic conditions [50].
Several studies have suggested that Cyclin D1 can induce cell
growth and protein synthesis in addition to its well-known effects
on proliferation [51,52]. In MCF7 cells, 4EBP1 was described as a
key modulator of Cyclin D1 therefore coupling its expression to
mTORC1 signaling [53]. Although Cyclin D1 is downstream of
all three pathways, it does not seem to be a rate limiting factor in
the proliferative response to amino acids in our system, suggesting
that Erk and p38 MAPK are affecting cell cycle progression and
proliferation by controlling expression of cyclin-dependent kinase
inhibitors such as p21 and p27 [44,54,55].
In conclusion, our studies demonstrate that overexpression of
CD98hc by renal tubular epithelial cells increases cell proliferation
by inducing signaling via its cytoplasmic tail and increasing CD98-
dependent amino acid transport. These data have ramifications if
CD98hc is viewed as a therapeutic target in oncological and
immunological diseases. To this end CD98 has clearly been shown
to play a role in the pathogenesis of these diseases in mice
[27,28,30] and there is strong correlative data linking CD98
expression and tumor metastasis in humans [56–61].
Material and Methods
Antibodies and Other Reagents
The hybridoma cell line 4F2 (C13) (anti-CD98) was purchased
from American Type Culture Collection (ATCC, Manassas, VA)
and the anti-CD98 (4F2) antibody was purified from conditioned
medium from the hybridoma cell lines by protein A affinity
chromatography. We raised a polyclonal antibody to Lat-1
directed against the peptide sequence RHRKPEL found in the
N-terminus of human Lat-1. This antibody has been commercial-
ized by Capralogics (Hardwick, MA, USA). The specificity of this
antibody was verified with another Lat-1 antibody (clone 3B11-
1D, Serotec, Oxford, UK). Antibodies to phosphorylated and total
Erk1/2, p38 MAPK, Akt , p70S6K, 4EBP1 and Cyclin D1 were
all from Cell Signaling Technology (Beverly, MA). LY294002,
U0126, SB203580, rapamycin and PP242 were all purchased from
Calbiochem (EMD Biosciences, La Jolla, CA). Culture media were
from Mediatech (Manassas, VA) and the selection antibiotics
Geneticin and Zeocin were from Invitrogen (Carlsbad, CA).
3H-
Isoleucine (Ile) (77 Ci/mM) was purchased from Amersham
Pharmacia Biotech (Piscataway, NJ).
3H-Thymidine (6.7 Ci/
mmol) was purchased from MP Biomedicals (Irvine, CA).
Plasmids and Cell Lines
Inner medullary collecting duct (IMCD) cells, which have been
previously described, were used in all experiments [62]. IMCD
cells expressing either CD98 or deletion mutants of CD98
(CD98-77, CD98-82 and CD98-87) were previously described
Figure 8. Schematic diagram demonstrating how CD98 regu-
lates cell proliferation. Overexpression of CD98 results in increased
cell proliferation which is dependent on MAPK signaling mediated by
the cytoplasmic (CT) domain and increases amino acid transport which
is dependent on the extracellular (EC) domain. CD98 overexpression
increases mTOR signaling but this has no effect on cell proliferation.
doi:10.1371/journal.pone.0040026.g008
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fl/fl IMCD cells were isolated from CD98hc
floxed mice as described previously [63]. These cells are
maintained in DMEM and 10% fetal calf serum. Established
cells lines were transfected with a construct expressing full length
human CD98 (hCD98) or vector only. Cells expressing hCD98
were selected using flow cytometry. IMCD cells expressing the
Cless mutant (kindly donated by Dr. M. Palacin (Universitat de
Barcelona)) [36,64] were generated by transfecting IMCD cells
using Lipofectamine Plus (Invitrogen) with the Cless construct
after which the cells were selected by adding Geneticin (G418
sulfate) (Invitrogen, Carlsbad, CA) at 1 mg/ml to the medium.
Stable cell populations of cells expressing equal levels of Cless,
CD98 and the mutants of CD98 were established utilizing flow
cytometry under sterile conditions.
Human Lat-1 cDNA was a generous gift from Dr. Francois
Verrey (University of Zurich). Cells overexpressing Lat-1 were
made by transfecting with the construct, after which they were
selected with Zeocin (400 mg/ml) and cloned. Multiple clones were
initially made and then transfected with CD98 or the mutant
CD98 constructs as described above and sorted to equal levels of
expression by flow cytometry.
Cell Survival Studies
Subconfluent monolayers (30–50%) of CD98
fl/fl or CD98
fl/fl
IMCD cells reconstituted with hCD98 were infected with adeno-
Cre for 16 hours. Lysates were isolated at 24 hr intervals following
infection and run on 10–15% SDS gels. Immunoblots were
probed with specific antibodies to human CD98 (Santa Cruz,C-
20) or mouse CD98 ( Santa Cruz, M-20) as well as cleaved
Caspase-3 (Cell Signaling Technology, MA) and Actin as a loading
control (Sigma-Aldrich).
Amino Acid Transport
The amino acid studies were performed as previously described
[17]. The wild type or transfected IMCD cells were rinsed with
warm Na
+-free Hanks’ buffered salt solution (HBSS) (136.6 mm
Choline Chloride, 5.4 mm KCl, 4.2 mm NaHCO3, 2.7 mm
Na2HPO4, 1 mmCaCl2, 0.5 mm MgCl2, 0.44 mm KH2PO4, 0.41
mmMgSO4, pH 7.8), in which the sodium-containing salts were
iso-osmotically replaced with choline, to remove extracellular Na
+
and amino acids. Cells were equilibrated in warm choline-
substituted HBSS for 10 min. The uptake of radiolabeled amino
acids (2 mCi of [
3H]Ile/ml) at 100 mmol/liter in 1 ml of choline-
substituted HBSS was measured for 20 s at 37uC. Uptake of
[
3H]Ile was linearly dependent on incubation time up to at least
3 min. Uptake was terminated by washing the cells rapidly four
times with 1 ml/well of ice-cold HBSS. The cells were lysed
overnight with 1 ml 0.2%SDS/2 ml NaOH. A 0.95-ml aliquot
from each well was mixed with scintillation fluid, and radioactivity
was quantified in a Beckman LS 6000SC liquid scintillation
counter. The remaining 0.1 ml was analyzed for protein content
using a BCA protein assay reagent.
Cell Proliferation Assay
3610
3 cells were plated per well in 96-well plates and
maintained in DMEM/F12 devoid of serum for 24 hours prior
to the experiment. When studying serum-dependent prolifera-
tion,
3H-Thymidine was added at 0.5 mCi/well in DMEM/F12
containing 1% FBS for up to 16 hours. When studying the effect
of amino acids on proliferation, cells were incubated in DPBS
containing glucose (3 g/L) and Ca
++/Mg
++ for 2 hours prior to
the 8 hour
3H-Thymidine pulse. When needed, pretreatment
with inhibitors was performed for up to an hour prior to the
assay. The cells were then washed repeatedly with PBS then 10%
Trichloroacetic Acid, solubilized with 1% SDS and radioactivity
was measured using a liquid scintillation counter (Beckman, CA).
Membrane Localization of CD98hc
To verify the proper compartmentalization of CD98 in cells
transfected with the deletion constructs, the cells were fractionated
into Triton X-100–soluble and –insoluble fractions, as described
previously [65]. Briefly, cells were scraped in cell lysis buffer
(10 mM HEPES, pH 7.2, 1% Triton X-100, 100 mM NaCl,
2 mM EDTA supplemented with protease and phosphatase
inhibitors), incubated at 4uC for 20 min, followed by centrifuga-
tion at 10,000 6 g for 20 min. The resulting supernatant was
considered the Triton X-100/detergent-soluble fraction. For the
insoluble fraction, the pellet was dissolved in solubilization buffer
(10 mM HEPES, pH 7.2, 1% SDS, 100 mM NaCl, 2 mM EDTA
supplemented with protease and phosphatase inhibitors), and the
proteins were released by sonication. The resulting preparation
was incubated at 4uC for 20 min, followed by centrifugation at
10,000 6g for 20 min. The resulting supernatant was considered
the TX-100/detergent-insoluble fraction. 10 mg of each fraction
was analyzed by Western blot using anti-hCD98 antibody.
Amino Acid Deprivation Studie
Cells were serum deprived for 24 hours, rinsed repeatedly with
PBS then incubated for 2 hours in PBS containing Ca
++/Mg
++
and glucose at a concentration identical to that in DMEM/F12
(3 g/L). Serum free DMEM/F12 was then added to cells at
different time points after which they were harvested for different
assays. Pretreatment with inhibitors was performed prior to being
treated with DMEM/F12. After establishing dose-response curves,
inhibitors were used at the following concentrations: the MEK
inhibitor U0126 10 mM, the p38 MAPK inhibitor SB203580
10 mM, the PI3K inhibitor LY294002 10 mM, the mTOR
pathway inhibitor Rapamycin 100 nM and the mTOR kinase
inhibitor PP242 2.5 mM.
Immunoblotting
Cells were serum starved overnight then stimulated with 10%
FBS or subjected to amino acid deprivation as described above
then lysed in cell lysis buffer (Cell Signaling Technology, MA)
supplemented with protease and phosphatase inhibitors (Sigma,
MO) at the time points indicated. After protein quantification total
cell lysates (5–30 ug/lane) were run on 10–15% SDS gels,
transferred to PVDF membranes (BioRad, CA) and blocked with
5% milk in TBS-T. Immunoblotting was performed with primary
antibodies in 3%BSA in TBS-T then HRP-conjugated secondary
antibodies in 5% milk/TBS-T and visualized using the ECL Plus
western blotting detection system.
Immunoprecipitation
Cells overexpressing CD98 or CD98 deletion mutants as well as
Flag-tagged human Lat-1 were lysed in a Triton X-100 based cell
lysis buffer (Cell Signaling Technology, MA) supplemented with
protease and phosphatase inhibitors. Pre-cleared protein lysates
were incubated overnight with a human specific CD98 antibody
(ATCC, Hybridoma cell line 4F2 C13) and Protein G sepharose
beads (GE Healthcare) and run on a 10% SDS gel under both
non-reduced and reduced (1 mM DTT) conditions. Immunoblots
were probed with human specific CD98 antibody (Santa Cruz) as
well as Flag antibody (Sigma, MO).
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The Student’s t-test was used for comparisons between two
groups and analysis of variance using Sigma Stat software was
used for statistical differences between multiple groups. P,0.05
was considered statistically significant.
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